Gladius Capital Management LP Biogen Inc. Transaction History

Gladius Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$222.59 - $267.94 $7,122 - $8,574	32 Added 29.36%	141 $36,000
Q3 2023 Oct 10, 2023	BUY	$253.3 - $285.89 $27,609 - $31,162	109 New	109 $29,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $35,628 - $49,128	183 New	183 $49,000
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $144,968 - $172,394	-773 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$193.77 - $244.14 $149,784 - $188,720	773 New	773 $163,000
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $921,018 - $1.02 Million	-4,200 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $591,835 - $925,699	2,731 Added 185.91%	4,200 $0
Q4 2018 Feb 15, 2019	BUY	$278.5 - $352.75 $409,116 - $518,189	1,469 New	1,469 $442,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.